コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 -12 medium containing 2 x amino acids and 5% fetal calf serum).
2 d Dulbecco's modified Eagle's medium and 10% fetal calf serum.
3 presence of tissue culture medium containing fetal calf serum.
4 lls cultured in growth medium containing 10% fetal calf serum.
5 cing agent hydrogen peroxide and slightly by fetal calf serum.
6 elet-derived growth factor BB and 2% or less fetal calf serum.
7 st of these dissolves without aggregation in fetal calf serum.
8 eration of WI38 cells in the presence of 10% fetal calf serum.
9 without trypsin in the presence of 5 to 10% fetal calf serum.
10 compared with cells cultured in 1% dialyzed fetal calf serum.
11 r DMEM media with or without pyruvate and 1% fetal calf serum.
12 ted with either 50% autologous plasma or 10% fetal calf serum.
13 d in essential modified Eagle's medium + 10% fetal calf serum.
14 ascites fluid, and to remove bovine IgG from fetal calf serum.
15 Dulbecco's modified Eagle's medium with 10% fetal calf serum.
16 astrocytic cell phenotype in the presence of fetal calf serum.
17 EMEM) alone or in EMEM supplemented with 10% fetal calf serum.
18 hosphate-buffered saline (PBS) buffer and in fetal calf serum.
19 venom phosphodiesterase, S1 nuclease and in fetal calf serum.
20 t complex was completely inactivated with 2% fetal calf serum.
21 supplemented with Lebovitz's L-15, mouse and fetal calf serum.
22 neonatal mouse calvariae, and cultured with fetal calf serum (10% for osteoblast-like cells and 2% f
23 aqueous buffer (PBS) or in media containing fetal calf serum (10%), is rapidly taken-up into culture
25 4 versus 19 +/- 6%, P = 0.01) as well as 10% fetal calf serum (19 +/- 7 versus 31 +/- 6%, P = 0.03).
27 le's minimal essential media (EMEM) with 10% fetal calf serum and Pluronic F-68 or F-127 in concentra
28 ells are grown in low serum conditions (0.1% fetal calf serum) and is observed selectively with trans
29 urrently used clinically (but which contains fetal calf serum), and a serum-free alternative, M2 (mel
31 after stimulation by lysophosphatidic acid, fetal calf serum, and epidermal growth factor retain act
34 ring glomerular injury, the effect of PF4 on fetal calf serum- and platelet-derived growth factor (PD
35 s with 12-O-tetradecanoylphorbol-13-acetate, fetal calf serum, anisomycin, UV irradiation, tumor necr
38 on in RPMI 1640 medium supplemented with 15% fetal calf serum at 37 degrees C with 5% CO(2) in air.
39 26695 cultured in brucella broth containing fetal calf serum (BBF) alone or supplemented with 100 mi
40 ss-galactosidase, bovine serum albumin, nor fetal calf serum caused an increase in outflow resistanc
41 of cell-based therapies using cells grown in fetal calf serum-containing media, an antibody response
45 ifically in response to IGF-I but not to 10% fetal calf serum, epidermal growth factor, fibroblast gr
47 te in Dulbecco's modified Eagle's medium and fetal calf serum, even with supplemental growth factors.
51 reduced by stimulation of proliferation with fetal calf serum (FCS) and platelet-derived growth facto
55 d to culture medium supplemented with 1) 15% fetal calf serum (FCS) only; 2) 1% FCS only; 3) 1% FCS a
56 s stimulated over 50-fold by the addition of fetal calf serum (FCS) to the cell culture medium (RPMI
58 e medium (minimum essential medium, MEM) and fetal calf serum (FCS) were probed by XANES and EXAFS.
60 parent deficiency and identified a factor in fetal calf serum (FCS) which is capable of mediating upt
62 were cultured in medium supplemented with 5% fetal calf serum (FCS), anti-CD3 antibody, and interleuk
63 n media containing various concentrations of fetal calf serum (FCS), bovine serum albumin, or porcine
64 rates as control cells when cultured in 0.5% fetal calf serum (FCS), but failed to undergo fetal calf
66 ured with adherent cells (macrophages) in 1% fetal calf serum (FCS)- or adult mouse serum (AMS)-suppl
67 telencephalic cells cultured in 0.5 or 2.0% fetal calf serum (FCS)-containing medium for 48 hr showe
68 nist concentration-dependent potentiation of fetal calf serum (FCS)-stimulated cell proliferation.
69 etal calf serum (FCS), but failed to undergo fetal calf serum (FCS)-stimulated hyperplasia when grown
71 microL TGF-beta2 (TGF-beta2-treated group), fetal calf serum (FCS)/phosphate-buffered saline (PBS; F
73 mbryonic MM cell line (or, similarly, by 10% fetal calf serum), forms branching tubules under three-d
76 f NPCCs was achieved in vitro by addition of fetal calf serum, insulin-like growth factor-I, nicotina
78 leukin-1, platelet-derived growth factor, or fetal calf serum, MCs initiated rapid HA synthesis assoc
79 forming growth factor beta-1 (TGF-beta1) and fetal calf serum on proteoglycan synthesis in corneal fi
81 % +/- 12% 48 hours after incubation with 10% fetal calf serum or epidermal growth factor (5 ng/mL), r
82 -steroidal ecdysone analog RH5992 for either fetal calf serum or larval extract also results in activ
83 fetal calf serum than in that grown with 15% fetal calf serum, suggesting that factors present in the
84 nergistic effect of Tpo was observed both in fetal calf serum-supplemented and serum-depleted medium
85 ted at a concentration of 1 cell per well in fetal calf serum-supplemented and serum-depleted medium.
86 ee medium (SFM) or SFM supplemented with 10% fetal calf serum, TGF-gamma1, TGF-beta2, TGF-beta3, basi
87 fetal cultures grown in the presence of 2.5% fetal calf serum than in that grown with 15% fetal calf
88 tion as well as the individual proteins from fetal calf serum that are associated with lipoplexes.
89 n both LPS-treated RAW 264.7 macrophages and fetal calf serum-treated mouse embryonic fibroblasts, TT
90 tion efficiency of the stable complex in 15% fetal calf serum was 30% of that obtained in the absence